[go: up one dir, main page]

BG104527A - Formulations comprising dissolved paroxetine - Google Patents

Formulations comprising dissolved paroxetine

Info

Publication number
BG104527A
BG104527A BG104527A BG10452700A BG104527A BG 104527 A BG104527 A BG 104527A BG 104527 A BG104527 A BG 104527A BG 10452700 A BG10452700 A BG 10452700A BG 104527 A BG104527 A BG 104527A
Authority
BG
Bulgaria
Prior art keywords
paroxetine
solid
formulations
solutions
dissolved
Prior art date
Application number
BG104527A
Other languages
Bulgarian (bg)
Inventor
Ahmad Ghazawi
Graham LEONARD
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BG104527A publication Critical patent/BG104527A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Pharmaceutical formulations of paroxetine are provided in which the paroxetine is in solution in a solid, semi-solid or liquid carrier. The solutions are used to fill capsules, or self-supporting solid solutions are shaped into solid dosage forms such as tablets of pellets. Also disclosed are novel liquid formulations in which a solubilising agent is used to solubilise paroxetine in oils and/or liquids, and methods of avoiding other parroxetine formed converting to the hemihydrate, by use of anhydrous or hydrophobic carriers or excipients. 19 claims
BG104527A 1997-11-21 2000-06-13 Formulations comprising dissolved paroxetine BG104527A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation
PCT/GB1998/003471 WO1999026625A1 (en) 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine

Publications (1)

Publication Number Publication Date
BG104527A true BG104527A (en) 2001-04-30

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104527A BG104527A (en) 1997-11-21 2000-06-13 Formulations comprising dissolved paroxetine

Country Status (24)

Country Link
EP (1) EP1033986A1 (en)
JP (1) JP2001523718A (en)
KR (1) KR20010032320A (en)
CN (1) CN1279608A (en)
AP (1) AP2000001821A0 (en)
AR (1) AR015485A1 (en)
AU (1) AU1168099A (en)
BG (1) BG104527A (en)
BR (1) BR9814220A (en)
CO (1) CO4970832A1 (en)
DZ (1) DZ2658A1 (en)
EA (1) EA200000552A1 (en)
GB (1) GB9724544D0 (en)
HU (1) HUP0100580A3 (en)
IL (1) IL136106A0 (en)
MA (1) MA24704A1 (en)
NO (1) NO20002590L (en)
OA (1) OA11385A (en)
PE (1) PE20000381A1 (en)
PL (1) PL340555A1 (en)
SK (1) SK7342000A3 (en)
TR (1) TR200001423T2 (en)
WO (1) WO1999026625A1 (en)
ZA (1) ZA9810637B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
CA2367402C (en) * 1999-03-12 2010-11-23 Basf Aktiengesellschaft Stable pharmaceutical dosage form for paroxetine anhydrate
JP2003503493A (en) 1999-07-01 2003-01-28 イタルファルマコ ソシエタ ペル アチオニ Complexes of paroxetine with cyclodextrin or cyclodextrin derivatives
DE19930454A1 (en) * 1999-07-02 2001-01-04 Knoll Ag Solid paroxetine-containing preparations
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
JP2005531495A (en) * 2001-12-21 2005-10-20 シャイア ラボラトリーズ，インコーポレイテッド Oral capsule formulation with high physical stability
SE0200475D0 (en) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral pharmaceutical preparation
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
JP2013512948A (en) * 2009-12-08 2013-04-18 イル・ファ・カンパニー・リミテッド Solid dispersion comprising 20-O-β-D-glucopyranosyl-20 (S) -protopanaxadiol
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (en) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 Paroxetine mesylate capsule and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
SK95099A3 (en) * 1997-01-15 2000-01-18 Smithkline Beecham Plc Process for the preparation of free-flowing form of paroxetine hydrochloride, pharmaceutical composition containing same and use thereof

Also Published As

Publication number Publication date
AU1168099A (en) 1999-06-15
NO20002590L (en) 2000-07-19
PE20000381A1 (en) 2000-05-07
SK7342000A3 (en) 2000-12-11
EA200000552A1 (en) 2000-10-30
KR20010032320A (en) 2001-04-16
EP1033986A1 (en) 2000-09-13
CN1279608A (en) 2001-01-10
MA24704A1 (en) 1999-07-01
JP2001523718A (en) 2001-11-27
DZ2658A1 (en) 2003-03-22
PL340555A1 (en) 2001-02-12
OA11385A (en) 2004-01-27
IL136106A0 (en) 2001-05-20
AR015485A1 (en) 2001-05-02
CO4970832A1 (en) 2000-11-07
HUP0100580A2 (en) 2002-04-29
AP2000001821A0 (en) 2000-06-30
WO1999026625A1 (en) 1999-06-03
HUP0100580A3 (en) 2002-05-28
NO20002590D0 (en) 2000-05-19
BR9814220A (en) 2001-12-26
TR200001423T2 (en) 2000-10-23
ZA9810637B (en) 2000-05-22
GB9724544D0 (en) 1998-01-21

Similar Documents

Publication Publication Date Title
IL142801A0 (en) Pharmaceutical compositions containing an adenosine analog
NZ262679A (en) Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
FR2635265B1 (en) INTRAVENOUS PHARMACEUTICAL COMPOSITION COMPRISING CYCLOSPORIN AS ACTIVE INGREDIENT AND PROCESS FOR THE PREPARATION THEREOF
EP0402955A3 (en) Instrument for administering pharmaceutical tablets.
ES2191862T3 (en) LIQUID COMPOSITION INCLUDING AN HIV PROTEASE INHIBITOR AND A FATTY ACID OF C12-C18.
CA2168732A1 (en) Gelatin Capsules Containing a Highly Concentrated Acetaminophen Solution
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
ATE554750T1 (en) PREPARATIONS CONTAINING HYDROPHOBIC PHARMACEUTICAL ACTIVE INGREDIENTS
YU57600A (en) Bicyclic hydroxamic acid derivatives
MA24193A1 (en) PROCESSES FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE PEG-IFN ALPHA CONJUGATE, AND FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND THEIR USE
BG104527A (en) Formulations comprising dissolved paroxetine
ES2039480T3 (en) A LIQUID DOSAGE FORM FOR ORAL ADMINISTRATION OF A PHARMACEUTICALLY ACTIVE SUBSTANCE.
MY101784A (en) Novel pharmacological compounds
GB0016819D0 (en) Improvements in or relating to delivery capsules
FR2698788B1 (en) Effervescent pharmaceutical composition containing ibuprofen and process for its preparation.
EP0460062A4 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
GR1002847B (en) Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection
BE1002788A3 (en) PHARMACEUTICAL COMPOSITION CONTAINING A PLANT EXTRACT AND PROCESS FOR ITS PREPARATION.
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
IT8249241A0 (en) PHARMACEUTICAL COMPOSITION CONTAINING A FIBRINOLYTIC AGENT AND A DIFFUSION FACTOR, USEFUL FOR THE TREATMENT OF MYOCARDIAL INFARCTION
PT1144420E (en) PHOSPHATIDILINOSITOIS SULPHATATED TO ITS PREPARATION AND ITS UTILIZATION
IL113816A0 (en) Pharmaceutical compositions containing desogestrel their preparation and use
DE69416034D1 (en) Pharmaceutical preparation for rectal administration of pharmacologically active compounds
GB2213062A (en) Pharmaceutical preparation having oestrogen action
MY102368A (en) Solid sustained-release composition